...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study
【24h】

The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study

机译：吡格列酮的停用和每日剂量减少对2型糖尿病患者代谢参数的影响：一项回顾性纵向观察研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of the study was to understand the influences of withdrawal or dose reduction of pioglitazone in patients with type 2 diabetes.Methods: We retrospectively picked up patients who had undergone withdrawal or daily dose reduction of pioglitazone after a continuous prescription for 3 months or longer between January 2010 and March 2014. We compared the data before the withdrawal or dose reduction of pioglitazone with the data at 3 or 6 months after those by a chart-based analysis.Results: Among 713 patients taking pioglitazone at least once during the studied period, 20 patients had undergone withdrawal of pioglitazone (group A) and 51 patients had undergone daily dose reduction (group B). The mean pioglitazone dose at baseline was 23 mg in subjects of group A, and 30 mg in group B. The number of subjects who had taken high-dose metformin (≥ 1,000 mg) and dipeptidyl peptidase-4 (DPP-4) inhibitors increased after the withdrawal or dose reduction of pioglitazone in both groups. Although no significant change was observed in plasma glucose and HbA1c levels, body weight significantly decreased at 3 and 6 months after the dose reduction in group B. The same tendency was observed in group A. Serum high-density lipoprotein-cholesterol (HDL-C) levels significantly decreased at 3 and 6 months after the withdrawal in group A. The serum alanine aminotransferase levels significantly increased 3 months after the withdrawal in group A.Conclusions: Present study demonstrated that the withdrawal of pioglitazone exacerbated serum HDL-C and liver function in patients with type 2 diabetes, although glycemic control could be maintained by using high-dose metformin or DPP-4 inhibitors.J Clin Med Res. 2016;8(8):585-590doi: http://dx.doi.org/10.14740/jocmr2611w
机译：背景：本研究的目的是了解停药或减低吡格列酮对2型糖尿病患者的影响。方法：回顾性研究连续服用3个月处方药后停药或每日减量吡格列酮的患者。在2010年1月至2014年3月之间或更长时间。通过基于图表的分析，我们比较了吡格列酮停药或减量前的数据与术后3个月或6个月的数据。结果：在713例患者中，服用吡格列酮至少一次在研究期间，有20例患者停用了吡格列酮（A组），有51例患者每日减药（B组）。 A组受试者在基线时的吡格列酮平均剂量为23 mg，B组受试者为30 mg。服用高剂量二甲双胍（≥1,000 mg）和二肽基肽酶4（DPP-4）抑制剂的受试者人数增加两组均停用或降低吡格列酮剂量后。尽管血浆葡萄糖和HbA1c水平未见明显变化，但B组减量后3和6个月体重显着下降。A组也观察到相同趋势。血清高密度脂蛋白胆固醇（HDL-C ）在A组停药后3和6个月，血脂水平显着下降.A组停药后3个月，血清丙氨酸氨基转移酶水平显着升高。结论：本研究表明吡格列酮的停药加重了血清HDL-C和肝功能在2型糖尿病患者中，尽管可以通过使用大剂量二甲双胍或DPP-4抑制剂维持血糖控制。 2016; 8（8）：585-590doi：http：//dx.doi.org/10.14740/jocmr2611w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号